Oppenheimer adjusted its price target on Keros Therapeutics (NASDAQ:KROS) shares, reducing it significantly to $23.00 from ...

Keros Therapeutics (KROS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in ...

Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...

BofA analyst Jason Zemansky lowered the firm’s price target on Keros Therapeutics (KROS) to $32 from $33 and keeps a Buy rating on the shares.

Analyst Jason Zemansky of Bank of America Securities reiterated a Buy rating on Keros Therapeutics (KROS – Research Report), reducing the price ...

Keros Therapeutics, Inc. has announced a voluntary halt in dosing for the Tropos trial, a phase 2 clinical trial of ...

JPMorgan Chase & Co. JPM reported upbeat fourth-quarter FY24 results. Reported revenue rose 11% year-on-year to $42.8 billion. Net revenue (managed) was $43.7 billion (+10% Y/Y), beating the consensus ...

Hinge Bio raises $30M Series A for lupus drug; Keros halts trial dosing; Inflammasome reports eye treatment data; J&J files bladder cancer therapy; Verastem licenses KRAS drug ...

European shares were higher today. The eurozone's STOXX 600 surged 1.27%, Germany's DAX 40 gained 1.53% and France's CAC 40 gained 0.95%. Spain's IBEX 35 Index gained 1.20%, while London's FTSE 100 ...

US clinical-stage pharma Keros Therapeutics today announced that it has voluntarily halted all dosing in the TROPOS trial, a ...

Keros Therapeutics said on Wednesday it would voluntarily halt testing of an experimental blood pressure treatment due to ...

Taken together with Keros’ recent pivot away from obesity, the termination of its pulmonary arterial hypertension study could ...